Production of brain-derived neurotrophic factor by mononuclear cells of patients with multiple sclerosis treated with glatiramer acetate, interferon-β 1a, and high doses of immunoglobulins

Multiple Sclerosis

Volumn 13, Issue 3, 2007, Pages 313-331

  Sarchielli, Paola ^a   Zaffaroni, M ^b   Floridi, A ^a   Greco, L ^a   Candeliere, A ^a,c   Mattioni, A ^a,c   Tenaglia, S ^a,c   Di Filippo, M ^a,c   Calabresi, P ^a,c  

^a UNIVERSITY OF PERUGIA   (Italy)

^b Azienda Ospedaliera S Antonio Abate di Gallarate   (Italy)

^c IRCCS FONDAZIONE SANTA LUCIA   (Italy)

Author keywords

Brain derived neurotrophic factor; Glatiramer acetate; Immunoglobulins; Interferon beta 1a; Multiple sclerosis; Peripheral blood mononuclear cells

Indexed keywords

BETA1A INTERFERON; BRAIN DERIVED NEUROTROPHIC FACTOR; GAMMA INTERFERON; GLATIRAMER; IMMUNOGLOBULIN; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 5; METHYLPREDNISOLONE; MYELIN BASIC PROTEIN; PHYTOHEMAGGLUTININ;

ADULT; ARTICLE; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE COURSE; DRUG MEGADOSE; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMAN; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; NEUROPROTECTION; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; RELAPSE;

ADJUVANTS, IMMUNOLOGIC; ADULT; BRAIN; BRAIN-DERIVED NEUROTROPHIC FACTOR; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULINS; INTERFERON-BETA; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PEPTIDES; TIME FACTORS;

EID: 34248177331     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458506070146     Document Type: Article

References (57)

1. Schwartz M. Physiological approaches to neuroprotection: boosting of protective autoimmunity. Surv Ophthalmol 2001; 45: S256-60.
2. Moalem G, Leibowitz-Amit R, Yoles E, Mor F, Cohen IR, Schwartz M. Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nat Med 1999; 5: 49-55.
3. Kipnis J, Yoles E, Porat Z, Cohen A, Mor F, Sela M et al. T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies. Proc Natl Acad Sci USA 2000; 97: 7446-51.
4. Hammarberg H, Lidman O, Lundberg C, Eltayeb SY, Gielen AW, Muhallab S et al. Neuroprotection by encephalomyelitis: rescue of mechanically injured neurons and neurotrophin production by CNS-infiltrating T and natural killer cells. J Neurosci 2000; 20: 5283-91.
5. Ikeda K, Klinkosz B, Greene T, Cedarbaum JM, Wong V, Lindsay RM et al. Effects of brain-derived neurotrophic factor on motor dysfunction in wobbler mouse motor neuron disease. Ann Neurol 1995; 37: 505-11.
6. Neumann H, Wekerle H. Neuronal control of the immune response in the central nervous system: linking brain immunity to neurodegeneration. J Neuropathol Exp Neurol 1998; 57: 1-9.
7. Hohlfeld R, Kerschensteiner M, Stadelmann C, Lassmann H, Wekerle H. The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis. J Neuroimmunol 2000; 107: 161-66.
8. Skaper SD, Pollock M, Facci L. Mast cells differentially express and release active high molecular weight neurotrophins. Brain Res Mol Brain Res 2001; 97: 177-85.
9. Kerschensteiner M, Stadelmann C, Dechant G, Wekerle H, Hohlfeld R. Neurotrophic cross-talk between the nervous and immune systems: implications for neurological diseases. Ann Neurol 2003; 53: 292-304.
10. Correale J, Villa A. The neuroprotective role of inflammation in nervous system injuries. J Neurol 2004; 251: 1304-16.
11. Hauben E, Nevo U, Yoles E, Moalem G, Agranov E, Mor F et al. Autoimmune T cells as potential neuroprotective therapy for spinal cord injury. Lancet 2000; 355: 286-87.
12. Holtzman DM, Sheldon RA, Jaffe W, Cheng Y, Ferriero DM. Nerve growth factor protects the neonatal brain against hypoxic-ischemic injury. Ann Neurol 1996; 39: 114-22.
13. Binder DK, Scharfman HE. Brain-derived neurotrophic factor. Growth Factors 2004; 22: 123-31.
14. Marini AM, Jiang X, Wu X, Tian F, Zhu D, Okagaki P et al. Role of brain-derived neurotrophic factor and NF-kappaB in neuronal plasticity and survival: from genes to phenotype. Restor Neurol Neurosci 2004; 22: 121-30.
15. Askanas V. Neurotrophic factors and amyotrophic lateral sclerosis. Adv Neurol 1995; 68: 241-44.
16. Guillin O, Griffon N, Bezard E, Leriche L, Diaz J, Gross C et al. Brain-derived neurotrophic factor controls dopamine D3 receptor expression: therapeutic implications in Parkinson's disease. Eur J Pharmacol 2003; 480: 89-95.
17. Murer MG, Yan Q, Raisman-Vozari R. Brain-derived neurotrophic factor in the control human brain, and in Alzheimer's disease and Parkinson's disease. Prog Neurobiol 2001; 63: 71-124.
18. Fernandez-Espejo E. Pathogenesis of Parkinson's disease: prospects of neuroprotective and restorative therapies. Mol Neurobiol 2004; 29: 15-30.
19. Pezet S, Malcangio M. Brain-derived neurotrophic factor as a drug target for CNS disorders. Expert Opin Ther Targets 2004; 8: 391-99.
20. Hofer M, Pagliusi SR, Hohn A, Leibrock J, Barde YA. Regional distribution of brain-derived neurotrophic factor mRNA in the adult mouse brain. EMBO J 1990; 9: 2459-64.
21. Lewin GR, Barde Y-A. Physiology of the neurotrophins. Annu Rev Neurosci 1996; 19: 289-317.
22. Besser M, Wank R. Cutting edge: clonally restricted production of the neurotrophins brain-derived neurotrophic factor and neurotrophin-3 mRNA by human immune cells and Th1/Th2-polarized expression of their receptors. J Immunol 1999; 162: 6303-306.
23. Braun A, Lommatzsch M, Mannsfeldt A, Neuhaus-Steinmetz U, Fischer A, Schnoy N et al. Cellular sources of enhanced brain-derived neurotrophic factor production in a mouse model of allergic inflammation. Am J Respir Cell Mol Biol 1999; 21: 537-46.
24. Kerschensteiner M, Gallmeier E, Behrens L, Leal VV, Misgeld T, Klinkert WE et al. Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? J Exp Med 1999; 189: 865-70.
25. Cohen IR. The cognitive paradigm and the immunological homunculus. Immunol Today 1992; 13: 490-94.
26. Stadelmann C, Kerschensteiner M, Misgeld T, Bruck W, Hohlfeld R, Lassmann H. BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells? Brain 2002; 125: 75-85.
27. Sarchielli P, Greco L, Stipa A, Floridi A, Gallai V. Brain-derived neurotrophic factor in patients with multiple sclerosis. J Neuroimmunol 2002; 132: 180-88.
28. Gielen A, Khademi M, Muhallab S, Olsson T, Piehl F. Increased brain-derived neurotrophic factor expression in white blood cells of relapsing-remitting multiple sclerosis patients. Scand J Immunol 2003; 57: 493-97.
29. Caggiula M, Batocchi AP, Frisullo G, Angelucci F, Patanella AK, Sancricca C et al. Neurotrophic factors and clinical recovery in relapsing-remitting multiple sclerosis. Scand J Immunol 2005; 62: 176-82.
30. Petereit HF, Lindemann H, Schoppe S. Effect of immunomodulatory drugs on in vitro production of brain-derived neurotrophic factor. Mult Scler 2003; 9: 16-20.
31. Caggiula M, Batocchi AP, Frisullo G, Angelucci F, Patanella AK, Sancricca C et al. Neurotrophic factors in relapsing remitting and secondary progressive multiple sclerosis patients during interferon beta therapy. Clin Immunol 2006; 118: 77-82.
32. Ziemssen T, Kumpfel T, Klinkert WE, Neuhaus O, Hohlfeld R. Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor. Brain 2002; 125: 2381-91.
33. Ziemssen T. Neuroprotection and glatiramer acetate: the possible role in the treatment of multiple sclerosis. Adv Exp Med Biol 2004; 541: 111-34.
34. Ziemssen T, Kumpfel T, Schneider H, Klinkert WE, Neuhaus O, Hohlfeld R. Secretion of brain-derived neurotrophic factor by glatiramer acetate-reactive T-helper cell lines: implications for multiple sclerosis therapy. J Neurol Sci 2005; 233: 109-12.
35. Aharoni R, Kayhan B, Eilam R, Sela M, Arnon R. Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ. Proc Natl Acad Sci USA 2003; 100: 14157-62.
36. Aharoni R, Arnon R, Eilam R. Neurogenesis and neuroprotection induced by peripheral immunomodulatory treatment of experimental autoimmune encephalomyelitis. J Neurosci 2005; 25: 8217-28.
37. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 5O: 121-27.
38. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983; 33: 1444-52.
39. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996; 46: 907-11.
40. Koziol JA, Lucero A, Sipe JC, Romine JS, Beutler E. Responsiveness of the Scripps neurologic rating scale during a multiple sclerosis clinical trial. Can J Neurol Sci 1999; 26: 283-89.
41. Rovaris M, Inglese M, van Schijndel RA, Sormani MP, Rodegher M, Comi G et al. Sensitivity and reproducibility of volume change measurements of different brain portions on magnetic resonance imaging in patients with multiple sclerosis. J Neurol 2000; 247: 960-65.
42. Chen M, Valenzuela RM, Dhib-Jalbut S. Glatiramer acetate-reactive T cells produce brain-derived neurotrophic factor. J Neurol Sci 2003; 215: 37-44.
43. Weder C, Baltariu GM, Wyler KA, Gober HJ, Lienert C, Schluep M et al. Clinical and immune responses correlate in glatiramer acetate therapy of multiple sclerosis. Eur J Neurol 2005; 12: 869-78.
44. Neuhaus O, Farina C, Yassouridis A, Wiendl H, Then Bergh F, Dose T et al. Multiple sclerosis: comparison of copolymer-1-reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells Proc Natl Acad Sci USA 2000; 97: 7452-57.
45. Farina C, Bergh FT, Albrecht H, Meinl E, Yassouridis A, Neuhaus O et al. Treatment of multiple sclerosis with Copaxone (COP). Elispot assay detects COP-induced interleukin-4 and interferon-7 response in blood cells. Brain 2001; 124: 705-19.
46. Teitelbaum D, Aharoni R, Klinger E, Kreitman R, Raymond E, Malley A et al. Oral glatiramer acetate in experimental autoimmune encephalomyelitis: clinical and immunological studies. Ann N Y Acad Sci 2004; 1029: 239-49.
47. Arnon R, Aharoni R. Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications. Proc Natl Acad Sci USA 2004; 101: 14593-98.
48. Aharoni R, Yussim A, Sela M, Arnon R. Combined treatment of glatiramer acetate and low doses of immunosuppressive drugs is effective in the prevention of graft rejection. Int Immunopharmacol 2005; 5: 23-32.
49. Duda PW, Schmied MC, Cook SL, Krieger JI, Hafler DA. Glatiramer acetate (Copaxone®) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J Clin Invest 2000; 105: 967-76.
50. Gran B, Tranquill LR, Chen M, Bielekova B, Zhou W, Dhib Jalbut S et al. Mechanisms of immunomodulation by glatiramer acetate. Neurology 2000; 55: 1704-14.
51. LaSalle JM, Hafler DA. T cell anergy. FASEB J 1994; 8: 601-608.
52. Schmied M, Duda PW, Krieger JI, Trollmo C, Hafler DA. In vitro evidence that subcutaneous administration of glatiramer acetate induces hyporesponsive T cells in patients with multiple sclerosis. Clin Immunol 2003; 106: 163-74.
53. Lomen-Hoerth C, Shooter EM. Widespread neurotrophin receptor expression in the immune system and other nonneuronal rat tissues. J Neurochem 1995; 64: 1780-89.
54. Pan W, Banks WA, Fasold MB, Bluth J, Kastin AJ. Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology 1998; 37: 1553-61.
55. Rovaris M, Comi G, Rocca MA, Wolinsky JS, Filippi M; European/ Canadian Glatiramer Acetate Study Group. Short-term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications. Brain 2001; 124: 1803-12.
56. Wolinsky JS, Narayana PA, Johnson KP; Multiple Sclerosis Study Group and the MRI Analysis Center. United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Mult Scler 2001; 7: 33-41.
57. Rovaris M, Comi G, Filippi M. Can glatiramer acetate reduce brain atrophy development in multiple sclerosis? J Neurol Sci 2005; 233: 139-43.